Cell Therapies, Antibodies, Small Molecules
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
32
NCT05716919
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 9, 2023
Completion: Dec 31, 2023
Loading map...